Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney diseases. It also engages in the research and development, production, and sale of high-end interventional medical devices, such as cardiovascular and cerebrovascular, peripheral vascular, structural heart disease, electrophysiology, and cardiac rhythm management. The company was incorporated in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. operates as a subsidiary of Salubris Pharmaceuticals Co., Ltd.
Research context
Shenzhen Salubris Pharmaceuticals Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shenzhen Salubris Pharmaceuticals Co., Ltd is currently in a long term downtrend where the price is trading 11.4% below its 200 day moving average.
From a valuation standpoint, the stock is 43.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Shenzhen Salubris Pharmaceuticals Co., Ltd's total revenue sank by 33.3% to $604M since the same quarter in the previous year.
Its net income has dropped by 11759.5% to $-207M since the same quarter in the previous year.
Finally, its free cash flow fell by 78.4% to $22M since the same quarter in the previous year.
Based on the above factors, Shenzhen Salubris Pharmaceuticals Co., Ltd gets an overall score of 0/5.